Literature DB >> 12796124

Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury.

Zheqing Cai1, Dominador J Manalo, Guo Wei, E Rene Rodriguez, Karen Fox-Talbot, Huasheng Lu, Jay L Zweier, Gregg L Semenza.   

Abstract

BACKGROUND: Preconditioning phenomena provide evidence for adaptive responses to ischemia that have important implications for treatment/prevention of myocardial infarction. Hypoxia-inducible factor 1 (HIF-1) mediates adaptive transcriptional responses to hypoxia/ischemia. METHODS AND
RESULTS: Exposure of wild-type mice to intermittent hypoxia resulted in protection of isolated hearts against ischemia-reperfusion injury 24 hours later. Cardiac protection induced by intermittent hypoxia was lost in Hif1a+/- mice heterozygous for a knockout allele at the locus encoding HIF-1alpha. Erythropoietin (EPO) mRNA expression was induced in kidneys of wild-type mice subjected to intermittent hypoxia, resulting in increased plasma EPO levels. EPO mRNA expression was not induced in Hif1a+/- mice. EPO administration to rats increased functional recovery and decreased apoptosis in isolated hearts subjected to ischemia-reperfusion 24 hours later.
CONCLUSIONS: Hearts isolated from rodents subjected to intermittent hypoxia or EPO administration are protected against postischemic injury. Cardiac protection induced by intermittent hypoxia is critically dependent on Hif1a gene dosage. Our data suggest that additional studies to evaluate therapeutic applications of EPO administration are warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796124     DOI: 10.1161/01.CIR.0000078635.89229.8A

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  144 in total

Review 1.  Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning.

Authors:  Gregg L Semenza
Journal:  Biochim Biophys Acta       Date:  2010-08-21

2.  NF-kappaB driven cardioprotective gene programs; Hsp70.3 and cardioprotection after late ischemic preconditioning.

Authors:  Michael Tranter; Xiaoping Ren; Tiffany Forde; Michael E Wilhide; Jing Chen; Maureen A Sartor; Mario Medvedovic; W Keith Jones
Journal:  J Mol Cell Cardiol       Date:  2010-07-16       Impact factor: 5.000

Review 3.  Complex role of the HIF system in cardiovascular biology.

Authors:  Gabor Czibik
Journal:  J Mol Med (Berl)       Date:  2010-06-24       Impact factor: 4.599

4.  Effect of recombinant erythropoietin on ischemia-reperfusion-induced apoptosis in rat liver.

Authors:  Heba M Shawky; Sandra M Younan; Leila A Rashed; Heba Shoukry
Journal:  J Physiol Biochem       Date:  2011-09-28       Impact factor: 4.158

Review 5.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 6.  Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury.

Authors:  Z Z Chong; F Li; K Maiese
Journal:  Histol Histopathol       Date:  2005-01       Impact factor: 2.303

Review 7.  Winding through the WNT pathway during cellular development and demise.

Authors:  F Li; Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2006-01       Impact factor: 2.303

8.  Increased erythropoietin production after myocardial infarction in mice.

Authors:  M Mengozzi; R Latini; M Salio; A Sfacteria; G Piedimonte; J G Gerwien; M Leist; A L Siren; P Ghezzi; S Chimenti
Journal:  Heart       Date:  2006-06       Impact factor: 5.994

Review 9.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

10.  JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells.

Authors:  A C Breggia; D M Wojchowski; J Himmelfarb
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.